Welcome to our dedicated page for Dare Bioscience news (Ticker: $DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dare Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dare Bioscience's position in the market.
Rhea-AI Summary
Dare Bioscience, Inc. (NASDAQ: DARE) achieves technological proof of concept for DARE-LARC1, a long-acting contraceptive device with potential applications in diabetes, obesity, and other conditions requiring precise and prolonged treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.31%
Tags
-
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) secures $5 million at closing and up to $7 million of additional funding through a royalty-backed financing agreement. The investor is entitled to a percentage of royalties and milestones from Daré's global license agreement for XACIATO™ with Organon. The financing aims to drive shareholder value and advance late-stage product candidates, with the potential for Daré to terminate the agreement and revert future payments once the investor achieves a targeted return on investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Dare Bioscience, Inc. (NASDAQ: DARE) announces positive topline results from the Phase 1 study of DARE-PDM1, an investigational product designed to deliver diclofenac vaginally to treat primary dysmenorrhea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) receives a grant from the National Institutes of Health to support the clinical development of DARE-PTB1, an investigational intravaginal ring designed to reduce the risk of preterm birth. The company is eligible to receive up to $2 million in grant funding for its Phase 1 human clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ:DARE) has received FDA clearance for its investigational new drug (IND) application for DARE-VVA1, a novel non-hormonal treatment option for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) associated with menopause. The company can now plan for a Phase 2 clinical study of DARE-VVA1, addressing the unmet need for non-hormonal treatment options for women who cannot or choose not to use estrogen-based products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.78%
Tags
-
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) has announced the commencement of the Company’s pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive. The study aims to evaluate its effectiveness as a contraceptive along with its safety and usability. If successful, Daré expects the pivotal study to support marketing approvals of Ovaprene in the U.S. and other countries. The company has entered into a Cooperative Research and Development Agreement with the U.S. Department of Health and Human Services, represented by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, to collaborate on the pivotal Phase 3 study of Ovaprene. Additionally, Daré and Bayer announced an exclusive licensing agreement for U.S. commercial rights to Ovaprene.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) and Premier Research International, LLC extend their partnership agreement to support the clinical development of Daré’s reproductive health portfolio. The agreement aims to advance Daré’s product candidates in a timely and cost-efficient manner, leveraging Premier Research’s expertise in women’s health clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Dare Bioscience, Inc. (NASDAQ: DARE) and Strategic Science & Technologies, LLC (SST) announced the preliminary efficacy findings from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder (FSAD). The study demonstrated improvements in arousal, desire, and orgasm among women treated with Sildenafil Cream, supporting its potential for FDA approval to treat arousal disorder in women, addressing a critical unmet need in women's sexual health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
-
Rhea-AI Summary
Dare Bioscience, Inc. (NASDAQ: DARE) reported financial results and provided updates on XACIATO™, Ovaprene®, Sildenafil Cream, 3.6%, DARE-PDM1, and other products. The company is on track to achieve multiple milestones by the end of 2023, positioning itself for long-term success in women's health innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
Rhea-AI Summary
Daré Bioscience, Inc. announced that its President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will participate in several conferences in November 2023. The conferences include Collaborating for Novel Solutions (CNS) Summit 2023, Stifel 2023 Healthcare Conference, and Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
Dare Bioscience, Inc.
Nasdaq:DARE
DARE Rankings
DARE Stock Data
31.30M
98.89M
1.65%
6.63%
0.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN DIEGO
About DARE
daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.